-
Je něco špatně v tomto záznamu ?
Small-molecule activators of NRF1 transcriptional activity prevent protein aggregation
J. Sedlacek, Z. Smahelova, M. Adamek, D. Subova, L. Svobodova, A. Kadlecova, P. Majer, A. Machara, K. Grantz Saskova
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- aktivace transkripce účinky léků MeSH
- autofagie účinky léků MeSH
- Caenorhabditis elegans * účinky léků metabolismus MeSH
- faktor 1 související s NF-E2 metabolismus genetika MeSH
- knihovny malých molekul farmakologie MeSH
- lidé MeSH
- patologická konformace proteinů metabolismus farmakoterapie MeSH
- proteasomový endopeptidasový komplex * metabolismus MeSH
- proteinové agregáty * účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Intracellular protein aggregation causes proteotoxic stress, underlying highly debilitating neurodegenerative disorders in parallel with decreased proteasome activity. Nevertheless, under such stress conditions, the expression of proteasome subunits is upregulated by Nuclear Factor Erythroid 2-related factor 1 (NRF1), a transcription factor that is encoded by NFE2L1. Activating the NRF1 pathway could accordingly delay the onset of neurodegenerative and other disorders with impaired cell proteostasis. Here, we present a series of small-molecule compounds based on bis(phenylmethylen)cycloalkanones and their heterocyclic analogues, identified via targeted library screening, that can induce NRF1-dependent downstream events, such as proteasome synthesis, heat shock response, and autophagy, in both model cell lines and Caenorhabditis elegans strains. These compounds increase proteasome activity and decrease the size and number of protein aggregates without causing any cellular stress or inhibiting the ubiquitin-proteasome system (UPS). Therefore, our compounds represent a new promising therapeutic approach for various protein conformational diseases, including the most debilitating neurodegenerative diseases.
Department of Experimental Biology Palacky University Slechtitelu 27 Olomouc 78371 Czech Republic
Department of Organic Chemistry Charles University Hlavova 2030 8 Prague 2 12843 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010010
- 003
- CZ-PrNML
- 005
- 20250429134851.0
- 007
- ta
- 008
- 250415e20250129fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2025.117864 $2 doi
- 035 __
- $a (PubMed)39884031
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Sedlacek, Jindrich $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic; Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic
- 245 10
- $a Small-molecule activators of NRF1 transcriptional activity prevent protein aggregation / $c J. Sedlacek, Z. Smahelova, M. Adamek, D. Subova, L. Svobodova, A. Kadlecova, P. Majer, A. Machara, K. Grantz Saskova
- 520 9_
- $a Intracellular protein aggregation causes proteotoxic stress, underlying highly debilitating neurodegenerative disorders in parallel with decreased proteasome activity. Nevertheless, under such stress conditions, the expression of proteasome subunits is upregulated by Nuclear Factor Erythroid 2-related factor 1 (NRF1), a transcription factor that is encoded by NFE2L1. Activating the NRF1 pathway could accordingly delay the onset of neurodegenerative and other disorders with impaired cell proteostasis. Here, we present a series of small-molecule compounds based on bis(phenylmethylen)cycloalkanones and their heterocyclic analogues, identified via targeted library screening, that can induce NRF1-dependent downstream events, such as proteasome synthesis, heat shock response, and autophagy, in both model cell lines and Caenorhabditis elegans strains. These compounds increase proteasome activity and decrease the size and number of protein aggregates without causing any cellular stress or inhibiting the ubiquitin-proteasome system (UPS). Therefore, our compounds represent a new promising therapeutic approach for various protein conformational diseases, including the most debilitating neurodegenerative diseases.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a Caenorhabditis elegans $x účinky léků $x metabolismus $7 D017173
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a proteinové agregáty $x účinky léků $7 D066329
- 650 12
- $a proteasomový endopeptidasový komplex $x metabolismus $7 D046988
- 650 _2
- $a knihovny malých molekul $x farmakologie $7 D054852
- 650 _2
- $a autofagie $x účinky léků $7 D001343
- 650 _2
- $a faktor 1 související s NF-E2 $x metabolismus $x genetika $7 D051265
- 650 _2
- $a patologická konformace proteinů $x metabolismus $x farmakoterapie $7 D066263
- 650 _2
- $a aktivace transkripce $x účinky léků $7 D015533
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Smahelova, Zuzana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic; Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic
- 700 1_
- $a Adamek, Michael $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic; Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic
- 700 1_
- $a Subova, Dominika $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic; Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic; First Faculty of Medicine & General University Hospital, Charles University, U Nemocnice 2, Prague 2 12808, Czech Republic
- 700 1_
- $a Svobodova, Lucie $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic; Department of Organic Chemistry, Charles University, Hlavova 2030/8, Prague 2 12843, Czech Republic
- 700 1_
- $a Kadlecova, Alena $u Department of Experimental Biology, Palacky University, Slechtitelu 27, Olomouc 78371, Czech Republic
- 700 1_
- $a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic
- 700 1_
- $a Machara, Ales $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic. Electronic address: machara@uochb.cas.cz
- 700 1_
- $a Grantz Saskova, Klara $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 16610, Czech Republic; Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic. Electronic address: saskova2@natur.cuni.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 183 (20250129), s. 117864
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39884031 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134846 $b ABA008
- 999 __
- $a ok $b bmc $g 2311401 $s 1247091
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 183 $c - $d 117864 $e 20250129 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20250415
